VYGR - Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today? | Benzinga
Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), to advance potential gene therapies for Huntington's disease (HD) and spinal muscular atrophy (SMA).
Voyager will provide Novartis a target-exclusive license to access Voyager's TRACER capsids and other intellectual property for the respective diseases.
Voyager and Novartis will collaborate to advance a preclinical gene therapy candidate for HD.
"We are thrilled to expand our existing relationship with Novartis, a global ...